Literature DB >> 2326483

Stage T1 glottic carcinoma: results of radiation therapy or laser excision.

B E Epstein1, D J Lee, H Kashima, M E Johns.   

Abstract

A retrospective analysis was made of the data on 60 patients with stage T1 glottic carcinoma (43 T1a, 17 T1b) who received radiation therapy and 17 patients with T1a disease who underwent laser excision as the primary treatment modality. Patients who received radiation therapy achieved 3- and 5-year actuarial local control rates of 92% and 89% for T1a and 77% and 77% for T1b disease, respectively. In patients who underwent laser excision (all with T1a disease), the 3-year local control rate was 77%. Of the 42 evaluable irradiated T1a patients, 31 (74%) had a normal to near-normal voice, eight (19%) had mild or intermittent hoarseness, and three (7%) had persistent hoarseness. Of the 13 evaluable patients in the laser-excision group, four (31%) had a normal to near-normal voice, five (38%) had mild or intermittent hoarseness, and four (31%) had persistent hoarseness. The difference in the quality of voice between these two groups is statistically significant (P = .012), although the ultimate local control rate after salvage therapy for irradiated patients (97%) was similar to that for laser-excision patients (94%).

Entities:  

Mesh:

Year:  1990        PMID: 2326483     DOI: 10.1148/radiology.175.2.2326483

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

1.  Recent advances in management of laryngeal cancer.

Authors:  Youn Sang Shim
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

2.  Efficacy of laser surgery versus radiotherapy for treatment of glottic carcinoma: a systematic review and meta-analysis.

Authors:  Yongxia Ding; Binquan Wang
Journal:  Lasers Med Sci       Date:  2018-12-06       Impact factor: 3.161

3.  Endolaryngeal cordectomy using cold instruments for treatment of T1 glottic cancers.

Authors:  Fikret Kasapoglu; Levent Erisen; Hakan Coskun; Oğuz Basut
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-04-13       Impact factor: 2.503

4.  Usefulness of Semi-cylindrical Beam Spoiler in Treatment of Early Glottic Cancer Using 6 MV Photon Beam.

Authors:  Seong Soo Shin; Sohyun Ahn; Seung-Hyup Baek; Jungwon Kwak; Jin Sung Kim; Woo Sang Ahn
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 5.  Health status and voice outcome after treatment for T1a glottic carcinoma.

Authors:  A Jeanne G E Peeters; Christine D L van Gogh; Kim M Goor; Irma M Verdonck-de Leeuw; Johannes A Langendijk; Hans F Mahieu
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-01-09       Impact factor: 2.503

6.  The "gregorio marañon" hospital experience in the treatment of laryngeal carcinoma.

Authors:  M F Vega; T Martinez; B Scola; E Scola; S F Vega
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1997-07

7.  Conservative approaches to the management of voice disorders.

Authors:  Eberhard Kruse
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

8.  Evaluating Post-Radiotherapy Laryngeal Function with Laryngeal Videostroboscopy in Early Stage Glottic Cancer.

Authors:  Ariel E Marciscano; Vivek Charu; Heather M Starmer; Simon R Best; Harry Quon; Alexander T Hillel; Lee M Akst; Ana P Kiess
Journal:  Front Oncol       Date:  2017-06-12       Impact factor: 6.244

9.  SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.

Authors:  David L Schwartz; Alan Sosa; Stephen G Chun; Chiuxiong Ding; Xian-Jin Xie; Lucien A Nedzi; Robert D Timmerman; Baran D Sumer
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

10.  Comparison between transoral laser surgery and radiotherapy in the treatment of early glottic cancer: A systematic review and meta-analysis.

Authors:  André Vicente Guimarães; Rogério Aparecido Dedivitis; Leandro Luongo Matos; Felipe Toyama Aires; Claudio Roberto Cernea
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.